-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QCSLhlO4XvYKR0vOE3L9KX4ausbx/ehwawEn+b+JJedyQfXhTEXyVncYeIKUM3cz p19AyNmXt8EchP5E+tIRlg== 0001144204-04-014926.txt : 20040923 0001144204-04-014926.hdr.sgml : 20040923 20040923134057 ACCESSION NUMBER: 0001144204-04-014926 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040923 ITEM INFORMATION: Other Events FILED AS OF DATE: 20040923 DATE AS OF CHANGE: 20040923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 041042539 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 form8k.htm Unassociated Document
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 23, 2004
Date of Report
(Date of earliest event reported)


RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-30959
94-3199149
(Commission File Number)
(I.R.S. Employer Identification No.)


967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)



 
     
 
 


Item 8.01. Other Events and Required FD Disclosure.

On September 23, 2004, RITA Medical Systems, Inc., a Delaware corporation ("RITA"), announced that President and CEO Joseph DeVivo is scheduled to make an investor presentation at the UBS Global Life Sciences Conference at 9:30 a.m. EDT on Thursday, September30, 2004. A copy of RITA’s press release announcing this presentation is attached as Exhibit 99.1 hereto and incorporated by reference herein.



 
     
 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


RITA Medical Systems, Inc.



Date: September 23, 2004        By: /s/ Donald Stewart                                      
Donald Stewart, Chief Financial Officer and
Vice President Finance and Administration



 
     
 
 

RITA MEDICAL SYSTEMS, INC.

INDEX TO EXHIBITS


Exhibit Number
Description
  
     
99.1
Press Release of RITA Medical Systems, Inc. dated September 23, 2004.
  



 
 
 EX-99 2 ex99.htm Unassociated Document
RITA Medical Systems to Present at UBS Global Life Sciences Conference
September 23, 2004 08:55:00 AM ET
 
MOUNTAIN VIEW, Calif., Sept. 23 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. RITA today announced that President and CEO Joseph M. DeVivo is scheduled to make an investor presentation at the UBS Global Life Sciences Conference at 9:30 a.m. EDT on Thursday, September 30, 2004. The conference runs from September 27-30, 2004 at the Grand Hyatt in New York City.
 
DeVivo will be presenting on behalf of the Company, providing an overview on the recent merger, advances in product development and sales and marketing initiatives for the coming year.
 
A live webcast of the Company's presentation at the UBS Conference will be available via a link provided at www.RITAmedical.com.
 
About RITA Medical Systems, Inc.
 
RITA Medical Systems develops manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex(R) technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.
 
Certain statements in this news release may represent forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.
 
For further information, please contact: Investors, Matt Clawson, matt@allencaron.com, or Media, Len Hall, len@allencaron.com, both of Allen & Caron Inc, +1-949-474-4300, for RITA Medical Systems, Inc.; or Don Stewart, Chief Financial Officer, dstewart@ritamed.com, or Stephen Pedroff, VP Marketing Comm., spedroff@ritamed.com, both of RITA Medical Systems, Inc., +1-650-314-3400.
 
© 2004 PRNewswire
-----END PRIVACY-ENHANCED MESSAGE-----